Caplacizumab
Cablivi (caplacizumab) is an antibody pharmaceutical. Caplacizumab was first approved as Cablivi on 2018-08-30. It has been approved in Europe to treat thrombotic thrombocytopenic purpura. The pharmaceutical is active against von Willebrand factor.
| Trade Name | Cablivi |
|---|---|
| Common Name | Caplacizumab |
| Indication | thrombotic thrombocytopenic purpura |
| Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
